Lexaria Bioscience Corp. (LEXX) closed at $4.50 on November 6, 2026, up 7.9% from the previous close, on volume of 28,971 shares (30-day average 52,608).
Data as of November 6, 2026.
Lexaria Signs Third Pharmaceutical Agreement for DehydraTECH
TipRanks (Wed, 4-Nov 11:12 AM ET)
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
ACCESS Newswire (Wed, 4-Nov 9:00 AM ET)
Lexaria Celebrates its 70th Patent Award
ACCESS Newswire (Wed, 28-Oct 9:10 AM ET)
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
ACCESS Newswire (Wed, 21-Oct 9:25 AM ET)
Lexaria Announces Results from Animal Study GLP-1-A26-1
ACCESS Newswire (Thu, 15-Oct 9:10 AM ET)
Lexaria Highlights an $89 Billion Oral GLP-1 Opportunity as Novo Signals a Shift From Injections
Market Chameleon (Wed, 7-Oct 6:53 AM ET)
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
ACCESS Newswire (Tue, 6-Oct 9:10 AM ET)
Lexaria Highlights $4.60 Per Share Cash on Hand After $7.9 Million Capital Boost
Market Chameleon (Fri, 18-Sep 5:57 AM ET)
Lexaria Updates Financial Position
ACCESS Newswire (Thu, 17-Sep 9:10 AM ET)
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
ACCESS Newswire (Wed, 9-Sep 4:15 PM ET)
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Lexaria Bioscience Corp. trades on the NASDAQ stock market under the symbol LEXX.
As of November 6, 2026, LEXX stock price climbed to $4.50 with 28,971 million shares trading.
LEXX has a beta of 0.27, meaning it tends to be less sensitive to market movements. LEXX has a correlation of 0.00 to the broad based SPY ETF.
LEXX has a market cap of $9.48 million. This is considered a Sub-Micro Cap stock.
Last quarter Lexaria Bioscience Corp. reported $0 in Revenue and -$1.20 earnings per share. This fell short of revenue expectation by $-20,000 and missed earnings estimates by -$.30.
In the last 3 years, LEXX traded as high as $102.75 and as low as $2.43.
The top ETF exchange traded funds that LEXX belongs to (by Net Assets): VXF.
LEXX has underperformed the market in the last year with a return of -72.2%, while the SPY ETF gained +10.8%. In the last 3 month period, LEXX fell short of the market, returning -15.7%, while SPY returned -4.1%. However, in the most recent 2 weeks LEXX has outperformed the stock market by returning +46.1%, while SPY returned -3.2%.
LEXX support price is $3.72 and resistance is $4.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEXX shares will trade within this expected range on the day.
